cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30759148
title: Adjuvant roles of interleukin-7 in enhancing T cell recovery during antiretroviral therapy for individuals with HIV: a systematic review and meta-analysis

description: T cell suppression has been observed in individuals with human immunodeficiency virus (HIV) undergoing antiretroviral therapy (ART). This study aimed to evaluate the effect of interleukin (IL)-7 on T cell count and HIV DNA load in individuals with HIV receiving long-term ART. We screened English-language articles on PubMed, Embase, Cochrane, and Web of Science from inception up to April 7, 2023. The included articles were assessed using the Cochrane risk-of-bias assessment tool. A meta-analysis of CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts and HIV DNA load was performed in individuals with HIV before and after IL-7 administration. Eight articles were included in our study. CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts were significantly elevated at weeks 4 and 12 after administration of 20 μg/Kg IL-7 in individuals with HIV on long-term ART. The HIV DNA load in whole blood also increased after IL-7 treatment; however, no significant change was observed in intracellular DNA in peripheral blood mononuclear cells and CD4<sup>+</sup> T cells. Moreover, IL-7 is generally well tolerated in clinical studies. Our analysis revealed that IL-7 can induce an increase in CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts in individuals with HIV receiving long-term ART, aiding in immune system reconstitution and increasing the HIV DNA load in the whole blood. These findings suggest that while IL-7 holds promise as an adjuvant strategy for immune restoration, its long-term impact on HIV persistence must be weighed in clinical application.
DOI: 10.6084/m9.figshare.30759148.v1
title: Adjuvant roles of interleukin-7 in enhancing T cell recovery during antiretroviral therapy for individuals with HIV: a systematic review and meta-analysis

description: T cell suppression has been observed in individuals with human immunodeficiency virus (HIV) undergoing antiretroviral therapy (ART). This study aimed to evaluate the effect of interleukin (IL)-7 on T cell count and HIV DNA load in individuals with HIV receiving long-term ART. We screened English-language articles on PubMed, Embase, Cochrane, and Web of Science from inception up to April 7, 2023. The included articles were assessed using the Cochrane risk-of-bias assessment tool. A meta-analysis of CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts and HIV DNA load was performed in individuals with HIV before and after IL-7 administration. Eight articles were included in our study. CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts were significantly elevated at weeks 4 and 12 after administration of 20 μg/Kg IL-7 in individuals with HIV on long-term ART. The HIV DNA load in whole blood also increased after IL-7 treatment; however, no significant change was observed in intracellular DNA in peripheral blood mononuclear cells and CD4<sup>+</sup> T cells. Moreover, IL-7 is generally well tolerated in clinical studies. Our analysis revealed that IL-7 can induce an increase in CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts in individuals with HIV receiving long-term ART, aiding in immune system reconstitution and increasing the HIV DNA load in the whole blood. These findings suggest that while IL-7 holds promise as an adjuvant strategy for immune restoration, its long-term impact on HIV persistence must be weighed in clinical application.
DOI: 10.6084/m9.figshare.29144009
title: Determinants of stroke following percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis

description: Despite advances in the field, no systematic review has thoroughly documented the occurrence of stroke following Percutaneous Coronary Intervention (PCI) in patients with Acute Coronary Syndrome (ACS). This study aimed to investigate the factors contributing to stroke occurrence post-PCI in ACS patients. A systematic search of PubMed and EMBASE identified 2,369 articles. After full-text screening, 109 articles were included in the systematic review, with 55 articles selected for meta-analysis. Data from 18,466,823 patients across 109 studies were analyzed. Among these, 202,999 patients (1.1%) experienced post-PCI stroke. The participants' ages ranged from 49.0 to 87.6 years (mean 64.3 ± 6.2 years). The incidence of early post-PCI stroke within 30 days was 1.1%, while the incidence of stroke occurring &gt;30 days post-PCI was 1.8%, predominantly ischemic strokes. Predictors of stroke following PCI in ACS patients included traditional risk factors (i.e. female sex, older age, diabetes mellitus, hypertension, prior stroke or transient ischemic attack); comorbidities (i.e. chronic kidney disease, atrial fibrillation, anemia, high bleeding risk); and procedural factors (i.e. thrombus aspiration and Clopidogrel use). This study highlights the relatively low prevalence of stroke following PCI, estimated at approximately 1% of the studied population. These findings emphasize the critical need for continued vigilance in identifying and managing risk factors associated with post-PCI stroke in ACS patients. Future research should prioritize refining risk prediction models, developing innovative preventive strategies, and optimizing post-PCI care pathways to effectively reduce the incidence of stroke in this population.
DOI: 10.6084/m9.figshare.29144009.v1
title: Determinants of stroke following percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis

description: Despite advances in the field, no systematic review has thoroughly documented the occurrence of stroke following Percutaneous Coronary Intervention (PCI) in patients with Acute Coronary Syndrome (ACS). This study aimed to investigate the factors contributing to stroke occurrence post-PCI in ACS patients. A systematic search of PubMed and EMBASE identified 2,369 articles. After full-text screening, 109 articles were included in the systematic review, with 55 articles selected for meta-analysis. Data from 18,466,823 patients across 109 studies were analyzed. Among these, 202,999 patients (1.1%) experienced post-PCI stroke. The participants' ages ranged from 49.0 to 87.6 years (mean 64.3 ± 6.2 years). The incidence of early post-PCI stroke within 30 days was 1.1%, while the incidence of stroke occurring &gt;30 days post-PCI was 1.8%, predominantly ischemic strokes. Predictors of stroke following PCI in ACS patients included traditional risk factors (i.e. female sex, older age, diabetes mellitus, hypertension, prior stroke or transient ischemic attack); comorbidities (i.e. chronic kidney disease, atrial fibrillation, anemia, high bleeding risk); and procedural factors (i.e. thrombus aspiration and Clopidogrel use). This study highlights the relatively low prevalence of stroke following PCI, estimated at approximately 1% of the studied population. These findings emphasize the critical need for continued vigilance in identifying and managing risk factors associated with post-PCI stroke in ACS patients. Future research should prioritize refining risk prediction models, developing innovative preventive strategies, and optimizing post-PCI care pathways to effectively reduce the incidence of stroke in this population.
DOI: 10.6084/m9.figshare.28776421
title: Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis

description: Programmed death-1 (PD-1) inhibitors combined with chemotherapy have become a standard first-line treatment for advanced oesophageal squamous cell carcinoma (ESCC). Given the high costs associated with immunotherapy, evaluating the cost-effectiveness of different PD-1 inhibitors in the Chinese healthcare setting is essential for guiding treatment decisions and policy development. A cost-effectiveness analysis was conducted comparing six PD-1 inhibitors—sintilimab, toripalimab, tislelizumab, camrelizumab, serplulimab, and pembrolizumab—combined with chemotherapy for first-line treatment of advanced ESCC. A partitioned survival model was used to calculate incremental cost-effectiveness ratios (ICERs) from healthcare system perspective, with a willingness-to-pay (WTP) threshold set at $36,598.19 per quality-adjusted life year (QALY). Sensitivity analyses were performed to evaluate the robustness of the results. The ICERs for toripalimab, camrelizumab, pembrolizumab, serplulimab, sintilimab, and tislelizumab were $32,356.79/QALY, $48,410.64/QALY, $312,743.54/QALY, $121,200.84/QALY, $29,663.42/QALY, and $35,304.33/QALY, respectively. Sintilimab, toripalimab, and tislelizumab were below the WTP threshold. Among all regimens, the top three in life years (LYs) gained were toripalimab, serplulimab, and tislelizumab. Sensitivity analysis showed that utility values and drug prices were key factors influencing ICERs. Probabilistic analysis indicated that toripalimab, sintilimab, and tislelizumab had the highest probabilities of being cost-effective, at 83.1%, 81.4%, and 70.0%, respectively. Sintilimab, toripalimab, and tislelizumab are the most cost-effective PD-1 inhibitors when combined with chemotherapy for the first-line treatment of advanced ESCC in China, with ICERs below the WTP threshold. While all six PD-1 inhibitors demonstrated clinical benefits, pembrolizumab and serplulimab were less favourable from a cost-effectiveness standpoint. Sensitivity analysis confirmed that drug prices and utility values are significant determinants of cost-effectiveness.
DOI: 10.6084/m9.figshare.28776421.v1
title: Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis

description: Programmed death-1 (PD-1) inhibitors combined with chemotherapy have become a standard first-line treatment for advanced oesophageal squamous cell carcinoma (ESCC). Given the high costs associated with immunotherapy, evaluating the cost-effectiveness of different PD-1 inhibitors in the Chinese healthcare setting is essential for guiding treatment decisions and policy development. A cost-effectiveness analysis was conducted comparing six PD-1 inhibitors—sintilimab, toripalimab, tislelizumab, camrelizumab, serplulimab, and pembrolizumab—combined with chemotherapy for first-line treatment of advanced ESCC. A partitioned survival model was used to calculate incremental cost-effectiveness ratios (ICERs) from healthcare system perspective, with a willingness-to-pay (WTP) threshold set at $36,598.19 per quality-adjusted life year (QALY). Sensitivity analyses were performed to evaluate the robustness of the results. The ICERs for toripalimab, camrelizumab, pembrolizumab, serplulimab, sintilimab, and tislelizumab were $32,356.79/QALY, $48,410.64/QALY, $312,743.54/QALY, $121,200.84/QALY, $29,663.42/QALY, and $35,304.33/QALY, respectively. Sintilimab, toripalimab, and tislelizumab were below the WTP threshold. Among all regimens, the top three in life years (LYs) gained were toripalimab, serplulimab, and tislelizumab. Sensitivity analysis showed that utility values and drug prices were key factors influencing ICERs. Probabilistic analysis indicated that toripalimab, sintilimab, and tislelizumab had the highest probabilities of being cost-effective, at 83.1%, 81.4%, and 70.0%, respectively. Sintilimab, toripalimab, and tislelizumab are the most cost-effective PD-1 inhibitors when combined with chemotherapy for the first-line treatment of advanced ESCC in China, with ICERs below the WTP threshold. While all six PD-1 inhibitors demonstrated clinical benefits, pembrolizumab and serplulimab were less favourable from a cost-effectiveness standpoint. Sensitivity analysis confirmed that drug prices and utility values are significant determinants of cost-effectiveness.
DOI: 10.6084/m9.figshare.28024866
title: Prenatal genetic detection in foetus with gallbladder size anomalies: cohort study and systematic review of the literature

description: The aim of the study was to evaluate the detection rate of genetic abnormalities in cases of foetal gallbladder (FGB) size abnormalities to determine whether these abnormalities justify prenatal diagnosis. Two hundred and twenty-seven foetuses with gallbladder (GB) size anomalies who underwent prenatal diagnosis between January 2015 and June 2024 were included in the study. All these patients underwent chromosomal microarray and/or karyotyping, and 37 cases also underwent whole exome sequencing (WES). Two hundred and eight cases were followed up for postnatal outcomes. Then, we reviewed the literature of FGB anomalies cases with confirmed chromosomal results. The study included 227 foetuses, comprising 60 cases with isolated GB size anomalies and 167 cases with non-isolated GB size anomalies. Non-isolated GB size anomalies were associated with findings such as hyperechogenic bowel, ventriculomegaly, foetal growth restriction (FGR), cardiac anomalies, renal dysplasia and single umbilical artery. The overall diagnostic yield of genetic tests was 10.57% (24/227). Aneuploidies were identified in seven foetuses. Pathogenic/likely pathogenic copy number variations (CNVs) were found in nine foetuses, and α0-thalassemia in five foetuses. Additionally, three pathogenic single-nucleotide variants (SNVs) were detected through WES. Foetuses with non-isolated GB size anomalies showed a higher rate of detecting genetic abnormalities compared to those with isolated GB size anomalies, with a significant difference in statistical analysis (13.2% vs. 3.3%, <i>p</i> = .033, Chi-square test). A total of eight studies, involving 407 cases met the criteria for inclusion in the systematic review. Overall, 28 foetuses were identified to have chromosomal abnormalities (6.9%, 28/407). This study indicates that parents of foetuses with GB size anomalies should be informed about the potential for aneuploidy, pathogenic CNVs and SNVs, and genetic testing should be recommended in cases of non-isolated foetal GB size anomalies.
DOI: 10.6084/m9.figshare.28024866.v1
title: Prenatal genetic detection in foetus with gallbladder size anomalies: cohort study and systematic review of the literature

description: The aim of the study was to evaluate the detection rate of genetic abnormalities in cases of foetal gallbladder (FGB) size abnormalities to determine whether these abnormalities justify prenatal diagnosis. Two hundred and twenty-seven foetuses with gallbladder (GB) size anomalies who underwent prenatal diagnosis between January 2015 and June 2024 were included in the study. All these patients underwent chromosomal microarray and/or karyotyping, and 37 cases also underwent whole exome sequencing (WES). Two hundred and eight cases were followed up for postnatal outcomes. Then, we reviewed the literature of FGB anomalies cases with confirmed chromosomal results. The study included 227 foetuses, comprising 60 cases with isolated GB size anomalies and 167 cases with non-isolated GB size anomalies. Non-isolated GB size anomalies were associated with findings such as hyperechogenic bowel, ventriculomegaly, foetal growth restriction (FGR), cardiac anomalies, renal dysplasia and single umbilical artery. The overall diagnostic yield of genetic tests was 10.57% (24/227). Aneuploidies were identified in seven foetuses. Pathogenic/likely pathogenic copy number variations (CNVs) were found in nine foetuses, and α0-thalassemia in five foetuses. Additionally, three pathogenic single-nucleotide variants (SNVs) were detected through WES. Foetuses with non-isolated GB size anomalies showed a higher rate of detecting genetic abnormalities compared to those with isolated GB size anomalies, with a significant difference in statistical analysis (13.2% vs. 3.3%, <i>p</i> = .033, Chi-square test). A total of eight studies, involving 407 cases met the criteria for inclusion in the systematic review. Overall, 28 foetuses were identified to have chromosomal abnormalities (6.9%, 28/407). This study indicates that parents of foetuses with GB size anomalies should be informed about the potential for aneuploidy, pathogenic CNVs and SNVs, and genetic testing should be recommended in cases of non-isolated foetal GB size anomalies.
DOI: 10.6084/m9.figshare.30928082
title: Construction and validation of renal cell carcinoma tumor cell differentiation-related prognostic classification (RCC-TCDC): an integrated bioinformatic analysis and clinical study

description: Renal cell carcinoma (RCC) is a heterogeneous malignancy with diverse gene expression patterns, molecular landscapes, and differentiation characteristics of tumor cells. It is imperative to develop molecular RCC classification based on tumor cell differentiation for precise risk stratification and personalized therapy. We obtained scRNA-seq profiles from GSE159115 and bulk RNA-seq profiles from TCGA-KIRC cohort. We then performed scRNA-seq cluster analysis, monocle2 pseudotime analysis, and prognostic analysis to obtain tumor cell differentiation-related prognostic genes (TCDGs). Subsequently, we conducted consensus clustering to construct the RCC tumor cell differentiation-related prognostic classification (RCC-TCDC) and implemented prognostic and multi-omics analyses. Moreover, we utilized Lasso regression to help develop a multivariable prognostic model. In addition, we performed correlation analysis and Cmap algorithm for regulatory network establishment and candidate inhibitor prediction. We eventually included 370 kidney neoplasm patients in Xinhua cohort to undergo immunohistochemical staining and scoring for classification and comprehensive statistical analyses, including Chi-square tests, Kaplan-Meier survival analyses, and multivariable Cox regression analysis . 32 TCDGs were identifiedand RCC-TCDC was constructed to classify TCGA-KIRC patients into RCC-low differentiation (RCC-LD) (S100A11+ SH3BGRL3+, high risk), RCC-moderate differentiation (TSPAN7+, medium risk), and RCC-high differentiation (RCC-HD) (AQP1+ NPR3+, low risk). Notably, RCC-LD was validated as anindependent risk factor for both OS (<i>p</i> = 0.015, HR = 14.0, 95%CI = 1.67–117.8) and PFS (<i>p</i> = 0.010, HR = 4.0, 95%CI = 1.39–11.7) of RCC patients in Xinhua cohort, taking RCC-HD as reference. We constructed and validated a robust molecular classification system, RCC-TCDC, elucidating three distinct RCC subtypes.
DOI: 10.6084/m9.figshare.30928082.v1
title: Construction and validation of renal cell carcinoma tumor cell differentiation-related prognostic classification (RCC-TCDC): an integrated bioinformatic analysis and clinical study

description: Renal cell carcinoma (RCC) is a heterogeneous malignancy with diverse gene expression patterns, molecular landscapes, and differentiation characteristics of tumor cells. It is imperative to develop molecular RCC classification based on tumor cell differentiation for precise risk stratification and personalized therapy. We obtained scRNA-seq profiles from GSE159115 and bulk RNA-seq profiles from TCGA-KIRC cohort. We then performed scRNA-seq cluster analysis, monocle2 pseudotime analysis, and prognostic analysis to obtain tumor cell differentiation-related prognostic genes (TCDGs). Subsequently, we conducted consensus clustering to construct the RCC tumor cell differentiation-related prognostic classification (RCC-TCDC) and implemented prognostic and multi-omics analyses. Moreover, we utilized Lasso regression to help develop a multivariable prognostic model. In addition, we performed correlation analysis and Cmap algorithm for regulatory network establishment and candidate inhibitor prediction. We eventually included 370 kidney neoplasm patients in Xinhua cohort to undergo immunohistochemical staining and scoring for classification and comprehensive statistical analyses, including Chi-square tests, Kaplan-Meier survival analyses, and multivariable Cox regression analysis . 32 TCDGs were identifiedand RCC-TCDC was constructed to classify TCGA-KIRC patients into RCC-low differentiation (RCC-LD) (S100A11+ SH3BGRL3+, high risk), RCC-moderate differentiation (TSPAN7+, medium risk), and RCC-high differentiation (RCC-HD) (AQP1+ NPR3+, low risk). Notably, RCC-LD was validated as anindependent risk factor for both OS (<i>p</i> = 0.015, HR = 14.0, 95%CI = 1.67–117.8) and PFS (<i>p</i> = 0.010, HR = 4.0, 95%CI = 1.39–11.7) of RCC patients in Xinhua cohort, taking RCC-HD as reference. We constructed and validated a robust molecular classification system, RCC-TCDC, elucidating three distinct RCC subtypes.
DOI: 10.6084/m9.figshare.30517841
title: Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis

description: Systemic light chain (AL) amyloidosis is associated with a high mortality rate, particularly in the first year after diagnosis. Minimal residual disease (MRD) assessment plays a key role in the prognosis of AL amyloidosis but is typically performed later in the treatment process, thereby limiting its ability to guide early interventions. This retrospective study included 53 newly diagnosed AL amyloidosis patients who underwent MRD assessment <i>via</i> flow cytometry after two chemotherapy cycles. The aim of this study was to assess the effect of early MRD negativity on organ response kinetics and prognosis. After two chemotherapy cycles, 22.6% (12/53) of patients achieved early MRD negativity. Daratumumab-treated patients had a significantly greater early MRD negativity rate (41.46%/0%, <i>p</i> = 0.019). Early MRD-negative patients had a significantly longer event-free survival (EFS) (not reached vs. 37.48 months, <i>p</i> = 0.029) than MRD-positive patients. In terms of organ response, early MRD-negative patients with cardiac or renal involvement had higher complete response (CR) rates and significantly shorter times to cardiac and renal CR (cardiac CR = 5.6 months vs. 28.4 months, <i>p</i> = 0.009; renal CR = 12.2 months vs. 41.0 months; <i>p</i> &lt; 0.001). Early MRD negativity predicts faster/deeper organ responses in AL amyloidosis patients and is associated with improved prognosis. These findings offer new possibilities for integrating early MRD assessment into clinical practice. Early MRD negativity in AL amyloidosis patients leads to faster, deeper organ responses and significantly better event-free survival.Daratumumab-based induction therapy enhances early MRD negativity rates and improves prognosis, especially in cardiac and renal responses. Early MRD negativity in AL amyloidosis patients leads to faster, deeper organ responses and significantly better event-free survival. Daratumumab-based induction therapy enhances early MRD negativity rates and improves prognosis, especially in cardiac and renal responses.